Sector News

UK drug contractor to be sold to private equity firm in $1.4B deal

May 30, 2021
Life sciences

The Carlyle Group created Bidco to buy Vectura, which specializes in inhalers and works with major drugmakers from Novartis to GlaxoSmithKline. The company’s technology is used in 13 inhaled and 11 non-inhaled products, according to a statement on the deal.

Vectura also has a portfolio of treatments in development with partners, the companies said, although it’s been less successful in bringing its own drugs to market. Vectura shelved an asthma therapy in 2018 after it failed in a Phase 3 study.

The purchase is part of a wave of investment firms buying up contractors in the pharmaceutical business. With medicines becoming increasingly complex, biotechs and traditional pharma companies are relying more and more on specialists to develop and manufacture new therapies. READ MORE

By Kristin Jensen

Source: biopharmadive.com

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).